Chris Michael Property Group Reveals How Digital Nomads & Retirees Reshape Cyprus Property Market

Chris Michael Property Group Reveals How Digital Nomads & Retirees Reshape Cyprus Property Market
Digital lifestyles and retirement trends are driving big changes in Cyprus real estate, with new buyer profiles reshaping the property landscape.

Limassol – August 7, 2025 – Chris Michael Property Group, a leading name in the Cyprus real estate market since 1982, highlights how digital nomads and retirees are transforming demand for residential property in Cyprus. With lifestyle-based migration on the rise, the company has seen a notable shift in buying patterns and long-term rental preferences in key locations like Limassol.

Properties-in-Limassol

The growing appeal of Cyprus as a hub for remote workers and retirees is driven by the island’s warm climate, favorable tax conditions, and evolving residency laws. Digital nomads, in particular, seek modern apartments to rent in Limassol with coworking proximity, reliable internet, and coastal views. At the same time, retirees are looking for peaceful, long-term homes with access to healthcare and local amenities.

“Requests for properties in Limassol have increased significantly from international clients aged between 30 and 60. Digital nomads prefer contemporary flats in the city centre, while retirees are leaning toward a house for sale in Limassol located near quieter suburban or coastal areas. We tailor our approach based on the buyer’s lifestyle needs, not just the size of the property,” said a spokesperson for the company.

New legislation has simplified the path for non-EU citizens to acquire property and residence permits, which has led to strong interest in both apartments for sale in Limassol Cyprus and long-term rentals. Digital nomads are opting for fully furnished apartments to rent in Limassol, often signing leases for 6 to 12 months. Retirees, on the other hand, explore ownership options like flats for sale Limassol or detached homes suitable for permanent relocation.

“Cyprus has become a flexible destination for global citizens. We are not only selling homes, but we are also helping clients build a new chapter. From finding an ideal house for sale in Limassol Cyprus to navigating residence applications, our team delivers long-term value through experience and precision,” the spokesperson said.

With over 40 years in the sector, Chris Michael Property Group continues to guide international buyers in finding the right property in Cyprus, adapting services to meet evolving market demands from retirees and remote workers alike.

About Company:

Chris Michael Property Group is a trusted real estate agency in Cyprus specialised in buying, selling, and renting properties. With years of experience in the market, the company helps clients find the best homes and investment opportunities in Limassol and beyond. Visit https://chris-michael.com.cy/

Media Contact
Company Name: Chris Michael Property Group
Contact Person: Chris Michael
Email: Send Email
Phone: +357 25 313 135
Address:Amathountos Avenue 108A Renanda Block A, office No. 1-3
City: Limassol
Country: Cyprus
Website: https://chris-michael.com.cy/

Chronic Idiopathic Urticaria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, No

“Chronic Idiopathic Urticaria Pipeline Analysis”
DelveInsight’s, “Chronic Idiopathic Urticaria (CIU) – Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria (CIU) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s analysis reveals that over 15 leading companies are actively engaged in the development of more than 20 therapeutic candidates for the treatment of Chronic Idiopathic Urticaria.

Chronic Idiopathic Urticaria Overview:

Chronic Urticaria (CU) refers to recurrent wheals that appear on most days for a duration of at least six weeks. It is categorized into chronic spontaneous urticaria (CSU), which has no identifiable cause, and chronic inducible urticaria (CIndU), which is triggered by specific physical stimuli.

Most CU cases are sporadic and self-limiting. CSU, previously known as chronic idiopathic urticaria, is now understood to have an autoimmune component in many instances.

Although the precise cause of CSU remains unknown, it is thought to involve autoimmune dysfunction in which autoantibodies target IgE and its receptors, resulting in histamine release from mast cells and basophils. Approximately 40% of CSU patients show a positive autologous serum skin test (ASST), and around one-third test positive for the basophil histamine release assay (BHRA), suggesting the presence of autoantibodies against IgE receptors.

Request for a detailed insights report on Chronic Idiopathic Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Chronic Idiopathic Urticaria Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Idiopathic Urticaria Therapeutics Market.

Key Takeaways from the Chronic Idiopathic Urticaria Pipeline Report

  • DelveInsight’s Chronic Idiopathic Urticaria pipeline report highlights an active and evolving landscape, with over 15 companies engaged in the development of more than 20 potential treatment options for the condition. Notable players such as United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, and Celldex Therapeutics are exploring innovative drug candidates to enhance the therapeutic landscape for Chronic Idiopathic Urticaria.

  • Several promising therapies are currently in various stages of development, including CMAB007, Barzolvolimab, and AK006. In a recent development from October 2025, Jasper Therapeutics launched an open-label extension study for Chronic Spontaneous Urticaria (CSU), enrolling participants from its prior BEACON and SPOTLIGHT trials. The company also received regulatory clearance in both the US and EU to include a 360mg single-dose cohort (n=4) in the BEACON trial. Preliminary results from doses up to 240mg are expected by January 2025, with findings from the 360mg group anticipated in the first half of 2025.

Chronic Idiopathic Urticaria Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Chronic Idiopathic Urticaria Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Idiopathic Urticaria treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Idiopathic Urticaria market.

Download our free sample page report on Chronic Idiopathic Urticaria pipeline insights

Chronic Idiopathic Urticaria Emerging Drugs

  • CMAB007: Taizhou Mabtech Pharmaceutical Co. Ltd.

  • Barzolvolimab: Celldex Therapeutics

  • AK006: Allakos

Chronic Idiopathic Urticaria Companies

Around 15 or more major companies are actively involved in developing treatments for Chronic Idiopathic Urticaria, with Taizhou Mabtech Pharmaceutical leading the way with a drug candidate currently in the most advanced stage of development—Phase III.

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Chronic Idiopathic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Chronic Idiopathic Urticaria Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Idiopathic Urticaria Therapies and Key Companies: Chronic Idiopathic Urticaria Clinical Trials and advancements

Chronic Idiopathic Urticaria Pipeline Therapeutic Assessment

• Chronic Idiopathic Urticaria Assessment by Product Type

• Chronic Idiopathic Urticaria By Stage

• Chronic Idiopathic Urticaria Assessment by Route of Administration

• Chronic Idiopathic Urticaria Assessment by Molecule Type

Download Chronic Idiopathic Urticaria Sample report to know in detail about the Chronic Idiopathic Urticaria treatment market @ Chronic Idiopathic Urticaria Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Chronic Idiopathic Urticaria Current Treatment Patterns

4. Chronic Idiopathic Urticaria – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Idiopathic Urticaria Late-Stage Products (Phase-III)

7. Chronic Idiopathic Urticaria Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Idiopathic Urticaria Discontinued Products

13. Chronic Idiopathic Urticaria Product Profiles

14. Chronic Idiopathic Urticaria Key Companies

15. Chronic Idiopathic Urticaria Key Products

16. Dormant and Discontinued Products

17. Chronic Idiopathic Urticaria Unmet Needs

18. Chronic Idiopathic Urticaria Future Perspectives

19. Chronic Idiopathic Urticaria Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Idiopathic Urticaria Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Idiopathic Urticaria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, No

Deep Partial-Thickness Thermal Burns Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | CUTISS AG, Skingenix, Polynovo, Mallinckrodt Pharmaceuticals, Kereci

“Deep Partial-Thickness Thermal Burns Pipeline”
Deep Partial-Thickness Thermal Burns Pipeline Insight, 2025″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Deep Partial-Thickness Thermal Burns market. A detailed picture of the Deep Partial-Thickness Thermal Burns pipeline landscape is provided, which includes the disease overview and Deep Partial-Thickness Thermal Burns treatment guidelines.

DelveInsight’s analysis reveals that over five key companies are actively involved in developing more than five treatment therapies for Deep Partial-Thickness Thermal Burns.

Deep Partial-Thickness Thermal Burns Overview

Deep partial-thickness thermal burns are a more severe type of burn injury that impact both the epidermis and a substantial portion of the dermis, often involving deeper structures like sweat glands and hair follicles. Unlike superficial partial-thickness burns, they penetrate deeper into the skin but do not extend entirely through the dermis as seen in full-thickness burns. These burns are typically characterized by a mottled red and white appearance, accompanied by blistering and areas of coagulated necrosis. Depending on severity, the wound may appear moist or dry. Pain is usually present but less intense than with superficial burns due to partial nerve damage, although the area remains sensitive to pressure.

Healing from deep partial-thickness burns generally takes between three to six weeks, with an elevated risk of hypertrophic scarring and contractures. Common causes include contact with flames, scalding liquids, hot surfaces, or extended exposure to heat sources, and in some cases, electrical or chemical burns. Effective treatment involves regular wound debridement and dressing changes to prevent infection, pain management using analgesics like NSAIDs or opioids, and the application of antimicrobial dressings or topical antibiotics. In more severe cases, intravenous fluid resuscitation may be necessary, and if healing is delayed or tissue loss is extensive, skin grafting could be required. Due to the complexity and depth of the injury, specialized care is essential to reduce the risks of infection, scarring, and long-term functional impairments.

Request for a detailed insights report on Deep Partial-Thickness Thermal Burns pipeline insights @ https://www.delveinsight.com/report-store/deep-partial-thickness-thermal-burns-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Deep Partial-Thickness Thermal Burns Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Deep Partial-Thickness Thermal Burns Therapeutics Market.

Key Takeaways from the Deep Partial-Thickness Thermal Burns Pipeline Report

  • DelveInsight’s report on the Deep Partial-Thickness Thermal Burns treatment pipeline highlights a dynamic and evolving landscape, with over five key companies actively engaged in developing more than five promising therapies.

  • Companies such as CUTISS AG, Skingenix, Polynovo, Mallinckrodt Pharmaceuticals, Kerecis, MediWound Germany GmbH, Kaken Pharmaceutical Co., Avita Medical, Vericel Corporation, KeraNetics, Integra Life Sciences Corporation, Medline Industries, Anika Therapeutics, ACell, Amryt Pharma, RenovaCare, and others are exploring innovative treatment options to enhance outcomes for patients suffering from deep partial-thickness burns.

  • Notable therapies under development include DenovoSkin, CellMist System, MW-III, among others, which are currently at various stages of clinical progress.

  • A landmark achievement in this space was the successful application of lab-grown skin derived from a patient’s own cells during a clinical trial in Melbourne. This groundbreaking approach has shown potential in reducing complications such as infection, pain, and scarring that are commonly associated with traditional skin grafts, marking a significant advancement in the field of burn care.

Deep Partial-Thickness Thermal Burns Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Deep Partial-Thickness Thermal Burns Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Deep Partial-Thickness Thermal Burns treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Deep Partial-Thickness Thermal Burns market.

Download our free sample page report on Deep Partial-Thickness Thermal Burns pipeline insights @ https://www.delveinsight.com/sample-request/deep-partial-thickness-thermal-burns-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Deep Partial-Thickness Thermal Burns Companies: CUTISS AG, Skingenix, Polynovo, Mallinckrodt Pharmaceuticals, Kerecis, MediWound Germany GmbH, Kaken Pharmaceutical Co., Avita Medical, Vericel Corporation, KeraNetics, Integra Life Sciences Corporation, Medline Industries, Anika Therapeutics, ACell, Amryt Pharma, Skingenix, RenovaCare

Deep Partial-Thickness Thermal Burns Companies

Over five major companies are currently engaged in the development of therapies targeting chronic deep partial-thickness thermal burns.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Deep Partial-Thickness Thermal Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Deep Partial-Thickness Thermal Burns Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Deep Partial-Thickness Thermal Burns Therapies and Key Companies: Deep Partial-Thickness Thermal Burns Clinical Trials and advancements @ https://www.delveinsight.com/report-store/deep-partial-thickness-thermal-burns-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Deep Partial-Thickness Thermal Burns Pipeline Therapeutic Assessment

• Deep Partial-Thickness Thermal Burns Assessment by Product Type

• Deep Partial-Thickness Thermal Burns By Stage

• Deep Partial-Thickness Thermal Burns Assessment by Route of Administration

• Deep Partial-Thickness Thermal Burns Assessment by Molecule Type

Download Deep Partial-Thickness Thermal Burns Sample report to know in detail about the Deep Partial-Thickness Thermal Burns treatment market @ Deep Partial-Thickness Thermal Burns Therapeutic Assessment @ https://www.delveinsight.com/sample-request/deep-partial-thickness-thermal-burns-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Content

1. Report Introduction

2. Executive Summary

3. Deep Partial-Thickness Thermal Burns Current Treatment Patterns

4. Deep Partial-Thickness Thermal Burns – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Deep Partial-Thickness Thermal Burns Late-Stage Products (Phase-III)

7. Deep Partial-Thickness Thermal Burns Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Deep Partial-Thickness Thermal Burns Discontinued Products

13. Deep Partial-Thickness Thermal Burns Product Profiles

14. Deep Partial-Thickness Thermal Burns Key Companies

15. Deep Partial-Thickness Thermal Burns Key Products

16. Dormant and Discontinued Products

17. Deep Partial-Thickness Thermal Burns Unmet Needs

18. Deep Partial-Thickness Thermal Burns Future Perspectives

19. Deep Partial-Thickness Thermal Burns Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Deep Partial-Thickness Thermal Burns Pipeline Reports Offerings: https://www.delveinsight.com/report-store/deep-partial-thickness-thermal-burns-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Deep Partial-Thickness Thermal Burns Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | CUTISS AG, Skingenix, Polynovo, Mallinckrodt Pharmaceuticals, Kereci

Moderate to Severe Plaque Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medic

“Moderate to Severe Plaque Psoriasis Pipeline Analysis”
DelveInsight’s, “Moderate To Severe Plaque Psoriasis – Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s analysis highlights that over 30 key companies are actively engaged in developing more than 30 treatment therapies for Moderate to Severe Plaque Psoriasis.

Moderate to Severe Plaque Psoriasis Overview:

Moderate to severe plaque psoriasis is the most common type of psoriasis, accounting for 80–90% of cases. It is an autoimmune condition that speeds up skin cell turnover, resulting in thick, scaly plaques typically found on the elbows, knees, scalp, and back. It can also impact the nails, causing issues such as discoloration, pitting, or nail separation. Flare-ups may be triggered by infections, stress, or skin trauma, with symptoms often coming and going.

The underlying cause of plaque psoriasis is not fully understood, but genetics are known to play a major role—about one-third of those affected have a family history. Specific gene mutations (PSORS1–PSORS9) have been associated with the condition, although environmental factors like infections or chemical exposure may also contribute. Diagnosis is usually clinical but may involve a skin biopsy to rule out other disorders.

The condition can have a profound effect on emotional and physical well-being. While it is chronic and currently incurable, treatment focuses on symptom control and reducing flare-ups. Standard treatment options include topical corticosteroids, UV light therapy, vitamin D3 analogs, and retinoids. Recent advances in immunological research have significantly improved the effectiveness of available treatments, enhancing patients’ quality of life.

Request for a detailed insights report on Moderate to Severe Plaque Psoriasis pipeline insights

“Moderate to Severe Plaque Psoriasis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Moderate to Severe Plaque Psoriasis Therapeutics Market.

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report

  • DelveInsight’s report on the Moderate to Severe Plaque Psoriasis pipeline highlights a dynamic and evolving landscape, with over 30 active companies engaged in developing more than 30 therapeutic candidates.

  • Notable players in this space include Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-Fite Biopharma, Bio-Thera Solutions, AbbVie, Sinocelltech, Janssen Research & Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra, and several others working to enhance the current treatment paradigm.

  • Several promising therapies are advancing through clinical stages, including candidates such as BMS-986165 and AK111.

  • In November 2025, Johnson & Johnson reported positive Phase III results for its oral drug, icotrokinra, in treating moderate-to-severe plaque psoriasis. The once-daily pill demonstrated substantial skin clearance and plaque severity reduction, with 64.7% of patients achieving clear or almost clear skin and 49.6% showing improvement in plaque severity by week 16—compared to 8.3% and 4.4% in the placebo group, respectively.

  • Additionally, in 2025, Arcutis Biotherapeutics saw a strong surge in market performance, reflecting its dermatology-focused pipeline. The company successfully launched three FDA-approved treatments in under two years and is targeting two more approvals by the end of 2025. Its lead product, Zoryve, treats both plaque psoriasis and seborrheic dermatitis and is also being formulated as a foam for eczema treatment.

Moderate to Severe Plaque Psoriasis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Moderate to Severe Plaque Psoriasis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Plaque Psoriasis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Moderate to Severe Plaque Psoriasis market.

Download our free sample page report on Moderate to Severe Plaque Psoriasis pipeline insights

Moderate to Severe Plaque Psoriasis Emerging Drugs

  • BMS-986165 : Bristol-Myers Squibb

  • AK111: Akeso Biopharma

Moderate to Severe Plaque Psoriasis Companies

Approximately 30 or more prominent companies are actively engaged in developing treatments for moderate to severe plaque psoriasis. Among these, Bristol-Myers Squibb leads with its drug candidates progressing to the most advanced stage—currently in the pre-registration phase.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Moderate to Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Moderate to Severe Plaque Psoriasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Moderate to Severe Plaque Psoriasis Therapies and Key Companies: Moderate to Severe Plaque Psoriasis Clinical Trials and advancements

Moderate to Severe Plaque Psoriasis Pipeline Therapeutic Assessment

• Moderate to Severe Plaque Psoriasis Assessment by Product Type

• Moderate to Severe Plaque Psoriasis By Stage

• Moderate to Severe Plaque Psoriasis Assessment by Route of Administration

• Moderate to Severe Plaque Psoriasis Assessment by Molecule Type

Download Moderate to Severe Plaque Psoriasis Sample report to know in detail about the Moderate to Severe Plaque Psoriasis treatment market @ Moderate to Severe Plaque Psoriasis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Moderate to Severe Plaque Psoriasis Current Treatment Patterns

4. Moderate to Severe Plaque Psoriasis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Moderate to Severe Plaque Psoriasis Late-Stage Products (Phase-III)

7. Moderate to Severe Plaque Psoriasis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Moderate to Severe Plaque Psoriasis Discontinued Products

13. Moderate to Severe Plaque Psoriasis Product Profiles

14. Moderate to Severe Plaque Psoriasis Key Companies

15. Moderate to Severe Plaque Psoriasis Key Products

16. Dormant and Discontinued Products

17. Moderate to Severe Plaque Psoriasis Unmet Needs

18. Moderate to Severe Plaque Psoriasis Future Perspectives

19. Moderate to Severe Plaque Psoriasis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Moderate to Severe Plaque Psoriasis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Moderate to Severe Plaque Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medic

Fifsee Relaunch: Revolutionizing Vacation Homes Hosting and Booking

We are thrilled to announce the re-launch of Fifsee, your all-in-one real estate ecosystem, now includes vacation homes hosting and booking. Fifsee is now packed with stronger features designed to unite buyers, sellers, tenants, landlords, service providers, hosts, and travelers. Now available on the App Store, soon on Google Play, Fifsee is set to redefine the property rental experience with an enhanced platform that connects users seamlessly while offering unparalleled benefits.

Enhanced Features for a Seamless Experience

Fifsee’s re-launch brings a robust set of tools to simplify the process of onboarding and managing property transactions. Whether you’re a seller looking to list your vacation home, a landlord seeking tenants, or a host aiming to attract travelers, Fifsee now offers an intuitive interface to connect and close deals efficiently. The platform’s upgraded features include real-time availability syncing, advanced search filters, and a streamlined booking system, ensuring a hassle-free experience for all users without needing any intermediaries.

Lowest Application Fee Advantage for Hosting your Rental space

One of the standout improvements in this launch is the introduction of an industry-leading low application fee. Fifsee is committed to maximizing your earnings by minimizing costs, allowing hosts to retain more of their revenue from your customer bookings. This competitive edge makes Fifsee the go-to platform for those looking to profit from their property listings without the burden of high fees.

Benefits of Renting Your Space

Renting out your vacation home with Fifsee opens up a world of opportunities. Here are some key benefits:

Earn Money Easily: Turn your unused space into a steady income stream with minimal effort. Fifsee’s platform handles the heavy lifting, from listing to booking.

Safe and Secure Payments: Partnering with Stripe, a trusted global payment processor, Fifsee ensures all transactions are secure, encrypted, and reliable. Hosts can receive payments with confidence, while guests enjoy peace of mind.

Wide Audience Reach: Connect with a global network of travelers, increasing your booking potential and visibility.

Flexible Hosting: Set your own availability and pricing, giving you full control over when and how you rent your space.

CEO Message:

As the CEO of Fifsee, I am incredibly excited to see our vision come to life with the launch of Vacation Homes. This re-launch marks a significant milestone for us, bringing a platform that not only connects people but also empowers them to unlock the potential of their properties. We are also working on adding AI features for all our users to enjoy several other interesting features in Fifsee, stay tuned!

Our low application fees and secure payment system via Stripe reflect our commitment to your success. I invite you to join us on this journey and experience the future of vacation home hosting and booking. Together, let’s create memorable stays and profitable opportunities!

Join the Fifsee Revolution

The re-launch of Fifsee marks a new chapter in vacation home hosting and booking. With its low service fees, enhanced features, and secure payment system via Stripe, Fifsee is poised to become the preferred platform for property owners and travelers alike. Whether you’re looking to rent out your space or book your next getaway, Fifsee offers a safe, profitable, and user-friendly solution. Download the app today from Appstore and start exploring the possibilities!

Soon available on Google Play and Web Hostings.

For Investors inquiries, contact:

Harni Raghavachary

Director, Press and Investor Relations

www.fifsee.com

https://fifsee.com/contact-us.php

Media Contact
Company Name: Fifsee
Contact Person: Harni Raghavachary
Email: Send Email
Country: United States
Website: https://www.fifsee.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fifsee Relaunch: Revolutionizing Vacation Homes Hosting and Booking

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Phyla, Dermata Therapeutics, Zydus Life

“Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Analysis”
DelveInsight’s “Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s analysis highlights that several key companies are actively engaged in developing treatment therapies for Severe Acne Vulgaris, also known as Severe Recalcitrant Nodular Acne.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Overview:

Severe Acne Vulgaris is an advanced form of common acne, marked by widespread inflammation, deep cysts, nodules, and potential scarring. It commonly appears on the face, chest, and back and is typically unresponsive to standard over-the-counter remedies.

Severe Recalcitrant Nodular Acne represents an even more persistent and severe type of nodular acne, featuring painful, inflamed nodules that are 5 mm or larger in diameter. The term “recalcitrant” indicates resistance to typical treatments such as topical medications and oral antibiotics. In such cases, isotretinoin is often the treatment of choice, known for its effectiveness in managing acne that doesn’t respond to conventional therapies.

Request for a detailed insights report on Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline insights

“Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Therapeutics Market.

Key Takeaways from the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Report

  • DelveInsight’s report on the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline highlights a dynamic landscape, with several companies actively developing new treatment options. Key players such as Phyla, Dermata Therapeutics, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Cutera, and others are working on innovative therapies aimed at improving outcomes for patients.

  • In October 2023, the FDA approved Cabtreo, a groundbreaking fixed-dose triple-combination topical gel containing clindamycin phosphate (1.2%), adapalene (0.15%), and benzoyl peroxide (3.1%). This formulation targets multiple acne-causing mechanisms, including inflammation, bacterial growth, and abnormal keratinization of hair follicles. Clinical studies reported significant reductions in both inflammatory and non-inflammatory lesions.

  • In June 2023, AviClear gained FDA clearance as a long-term treatment for mild to severe acne. This device employs a 1726nm laser to specifically target sebaceous glands, helping to control acne at its root. Results showed visible improvement in 90% of patients at six months, increasing to 92% at twelve months.

  • Additionally, recent research into at-home red-light therapy devices has revealed a 45.3% reduction in acne over four to twelve weeks. These devices, which help boost collagen and reduce inflammation, are emerging as effective adjunctive treatments when used alongside conventional acne therapies.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market.

Download our free sample page report on Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline insights

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Companies

  • Phyla, Dermata Therapeutics, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Cutera, and others.

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Companies

Several prominent companies are currently engaged in developing treatments for Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, with drug candidates progressing through mid to late stages of clinical development, particularly in Phase II and Phase III trials.

DelveInsight’s report covers products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Therapies and Key Companies: Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials and advancements

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Therapeutic Assessment

• Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Assessment by Product Type

• Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne By Stage

• Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Assessment by Route of Administration

• Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Assessment by Molecule Type

Download Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Sample report to know in detail about the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne treatment market @ Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Current Treatment Patterns

4. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Late-Stage Products (Phase-III)

7. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Discontinued Products

13. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Product Profiles

14. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Key Companies

15. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Key Products

16. Dormant and Discontinued Products

17. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Unmet Needs

18. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Future Perspectives

19. Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Phyla, Dermata Therapeutics, Zydus Life

LION Care Reviews: Unlock Deep Restful Sleep Naturally

Nowadays everything is fast paced. Our lives are in a constant rush where we are always chasing one thing after the other. It is stressful, extremely demanding and tiring. In such circumstances, wellness becomes a necessity rather than a luxury. While many people do various wellness practices such as yoga, fasting, relaxing, they still feel low, fatigued, they struggle with sleeping, and motivating themselves. Wellness practices such as yoga and meditation definitely work, but they are extremely time taking as you need to fully relax yourself to truly benefit from them. You need to find time, silence and peace of mind. The results also take longer to show as your body takes its own time to adjust to such practices. In the world of wellness, to make things easier, a new product called the LION Care Terahertz + Ionic Therapy Device is making rounds. This is an innovation launched to promote easy, low maintenance self-care.

What is LION Care?

LION Care is a user-friendly, multi functional tool designed to provide instant relief from sensory overload due to increased screen time and any other stress stored in your body. Now you may ask what type of sensory overload? LION Care helps protect your body from the effects of constant exposure to electronics like phones, laptops, and Wi-Fi. It does this by using a mix of gentle energy waves, helpful ions, and natural frequency support to bring your body back into balance.

The best thing about LION Care is that it provides wellness without relying on any additional supplements, applications, or medications. You only need this one tool to help you feel energized. LION Care is a tech-advanced way to bring betterment and wellness in your life without any complexity. It’s designed to stimulate natural healing, calm the nervous system, and optimize hydration and cellular function. It’s a sleek, beautifully designed, lightweight, clinically backed device designed for:

  • Relieving muscle tension and joint discomfort.

  • Improving circulation and oxygenation.

  • Supporting melatonin production for better sleep.

  • Enhancing hydration through structured water.

  • Restoring mental clarity and emotional balance.

How Does It Work?

LION Care operates on a simple dual functioning system:

1. Therapy Using Terahertz Frequency

Infrared and microwave frequencies are separated by terahertz waves. Human cells respond favorably to these gentle energy waves, which enhance circulation, encourage self-healing, and gently stimulate natural functions. Terahertz therapy is particularly effective at calming the nervous system, reducing inflammation, and rebalancing energy flow.

2. Ionic Activation

Ionic output helps increase melatonin production, raises blood oxygen levels, and supports nervous system recovery. It’s an essential feature for those suffering from insomnia, cognitive fatigue, or stress-related burnout.

Together, these two technologies create a combination that promotes deep rest, cellular renewal, and mind-body rejuvenation.

3. Enhanced Oxygen Flow

Terahertz energy boosts blood circulation, which delivers oxygen and nutrients to vital organs especially the brain. This helps with mental focus and energy.

4. Structured Water Therapy

You can even use LION Care to charge your drinking water. This increases hydration, promotes detoxification, and ensures your body gets maximum nutrient absorption.

How to Use LION Care?

LION Care is simple and easy to use. It does not require any doctor visits or any outside help. There are three easy application modes:

1. Direct Application: Apply the device directly to sore muscles, aching joints, or tension areas. It helps ease pain, reduce stiffness, and improve mobility. This is great for athletes, older adults, and anyone suffering from chronic discomfort.

2. Full-Body Therapy: You can gently glide the device over the entire body. This promotes energy flow, lowers fatigue, and increases circulation. As a result, you feel refreshed and recharged. Many users do this in the morning or before bed to feel refreshed or relaxed.

3. Structured Water Mode: Use LION Care to charge your drinking water. It can be run over your drinking water to structure it at a molecular level. This is done to increase hydration levels. Structured water is easier for your body to absorb, leading to better hydration and detoxification. This is helpful for people experiencing dehydration from screen time or indoor air environments.

Pricing:

LION Care is available in three options. They all come with FREE U.S. shipping and a 60-day money-back guarantee.

  • You can get 1 device for $499 (save $500).

  • 2 devices for $898 ($449 each, save $1,100).

  • 3 devices for $1,167 ($389 each, save $1,837).

Refund Policy:

LION Care has a solid 60-days refund policy. If it doesn’t help reduce muscle tension, improve your sleep, or fails to benefit you in any way, you’ll receive a full refund within 60 days of use.

Sleek Design and Easy to Use

LION Care is sleek, lightweight, and easy to handle. Its minimalist design fits comfortably in your hand and looks great on any desk or nightstand. There are no apps to install, no complicated settings, and no complicated tech knowledge needed. Just turn it on, glide it over your body or water and use it. Whether you’re at home, at work, or on the go, LION Care slips easily into your routine.

How Long Should You Use LION Care?

LION Care is super easy to use and doesn’t take much time. You can use it 2 to 4 times a day, with each session lasting about 4 to 40 minutes. In total, try to keep daily use under 2 hours.

It’s amazing for your body but using it too much in one day might make the effects less helpful or feel a bit uncomfortable. Start slow and see what feels best for you.

Final Thoughts:

LION Care is for anybody looking to care for themselves without putting in too much time or effort. It is extremely easy to use and handle and can be carried anywhere. It has multiple benefits starting from healing your body to providing you better sleep. LION Care supports preventive care and improves your mental health and resilience. In a world full of artificial fixes, LION Care brings you back to natural healing and restores your energy.

Media Contact
Company Name: News Zone
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://rebrand.ly/lioncare

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LION Care Reviews: Unlock Deep Restful Sleep Naturally

Mindologue Crowned “Best Mental Health App in the USA 2025”

“Co-Founder and CEO – Diana Renard”
Mindologue is the award-winning mental-wellness app that turns creativity into clarity. Snap or sketch a doodle and our AI decodes color, shape, and stroke to reveal what your emotions are really saying. It securely remembers your drawings, chats, and mood logs to build a living profile, then delivers personalized voice-guided meditations, context-aware support chats, and stunning visual breath-work effects, all in your pocket, anytime you need calm or insight.

Miami, Florida – August 7, 2025 – In a digital-first world searching for deeper emotional connection, Mindologue has emerged as the clear front-runner, earning the title “Best Mental Health App in the USA 2025”. Co-founded by visionary Diana Renard and former space-engineer and entrepreneur, turned CTO Fabrice Colozzi, Mindologue intertwines clinically grounded art-therapy principles with cutting-edge AI to deliver real-time emotional insight, bespoke meditations, and an elegant path to self-healing.

A Market Hungry for Better Help

The global mental-health-apps market is expected to surge from US $7.5 billion in 2025 to nearly US $24 billion by 2032 (18 % CAGR), with North America already commanding almost half of that revenue Fortune Business Insights. Against this backdrop of explosive growth, and an unprecedented demand for accessible, stigma-free care, Mindologue’s creativity-driven approach is rewriting the rulebook.

From Personal Struggle to Global Solution

Mindologue was born when Diana Renard confronted her own post-crisis recovery. “I’m not a licensed therapist; I’m a visionary building tools for a new generation of self-healers,” she explains. Frustrated by one-size-fits-all mood trackers and chatbots, Diana imagined an experience that felt as intuitive as sketching in a notebook yet as insightful as a seasoned counselor.

Enter Fabrice Colozzi, whose background in orbital systems engineering and AI research transformed that vision into reality. The duo prototyped an algorithm that analyzes color, stroke pressure, balance, and symbolism in user drawings, mapping those data points to evidence-based emotional markers. The result: a personalized “emotional fingerprint” delivered in seconds, no questionnaires, no judgment, just honest insight.

What Makes Mindologue Unmatched

Feature

Why It Matters

AI-Powered Drawing Analysis

Converts doodles into actionable emotional feedback in under 30 seconds.

Context-Aware AI Support Chat

A specially trained conversational agent that leverages insights from your artwork, past chats, and mood trends to deliver hyper-personal, therapist-style support and guidance, whenever you need it.

Tailored Meditations

Generates voice-guided sessions that match the user’s precise mood, avoiding generic scripts.

Mood Timeline & Insights

Tracks subtle emotional shifts over days or months, visualized in an intuitive dashboard.

Shareable Healing

Lets users share their custom meditations with friends or loved ones, extending support beyond the screen.

Immersive Visual Effects

Real-time animation (powered by a proprietary engine) deepens focus during meditation without distracting the user.

Voices Behind the Victory

Technology should not replace therapy; it should lower the threshold to begin healing. Mindologue gives people a safe, creative space to explore what they’re feeling. Our AI helps connect the dots.” – Diana Renard, Co-Founder & CEO

We engineered Mindologue like a spacecraft: robust, adaptive, and built to perform under pressure, because mental well-being deserves the same precision as any critical system.” – Fabrice Colozzi, Co-Founder & CTO

Clinicians have taken notice too. Art therapist Dr. Elena Morozova, who beta-tested the platform with trauma survivors, notes: “Patients who were reluctant to verbalize pain found their drawings ‘heard’ by the app. That alone broke down walls that months of talk therapy couldn’t.

Impact Beyond the Individual

According to the CDC, 1 in 5 adults in the United States live with a diagnosable mental health condition, yet fewer than half receive formal treatment. Mindologue fills that accessibility gap:

  • Cost-Effective: A fraction of typical therapy fees, with free core features.

  • Democratized Expertise: AI translates licensed-therapist techniques into everyday language.

  • 24/7 Availability: Support that travels with you, from subway commutes to sleepless nights.


Experience the Revolution

Media & Partnerships: press@mindologue.com

Media Contact
Company Name: Mindologue LLC
Contact Person: Sarah Cohen
Email: Send Email
Phone: 7862851360
Address:Biscayne Blvd
City: MIAMI
State: FL
Country: United States
Website: mindologue.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mindologue Crowned “Best Mental Health App in the USA 2025”

Listen First, Act Later: Former CIA Officer Dale Bendler Urges Citizens to Reclaim the Lost Art of Observation

Listen First, Act Later: Former CIA Officer Dale Bendler Urges Citizens to Reclaim the Lost Art of Observation

Dale Bendler
Ex–Chief of Station calls for a cultural shift away from digital noise and toward situational awareness, reflection, and meaningful civic attention

Miami, FL – August 7, 2025 – In an age of constant distraction, information overload, and short attention spans, retired CIA Chief of Station Dale Bendler is speaking out about the growing need for deeper observation, focused thinking, and strategic restraint in daily life. Drawing from over three decades in U.S. intelligence and special operations, Bendler is urging Americans to slow down, listen more, and rediscover what he calls “the quiet discipline” of attentiveness.

“You’ll notice more about human behaviour in 15 minutes of quiet walking than in an hour-long lecture,” Bendler said in a recent interview titled “Reflections from a Life in Intelligence and Quiet Purpose.” “We’ve lost something critical in the age of permanent noise—our capacity to see what’s actually happening around us.”

A Crisis of Attention

According to a 2023 Microsoft study, the average human attention span has dropped to just 8.25 seconds, lower than that of a goldfish. Meanwhile, Americans check their phones 344 times per day on average, with screen time topping 7 hours daily, per DataReportal’s 2024 Global Overview.

For Bendler, this is more than a lifestyle issue—it’s a vulnerability.

“In the field, I learned that the most dangerous people weren’t the ones shouting—they were the ones watching,” he said. “But today, most people are doing the shouting. Very few are doing the watching.”

Bendler believes this shift has not only eroded personal awareness but also dulled society’s ability to interpret real-world risks, political manipulation, and social dynamics with nuance.

A Call to Individual Action

Unlike traditional public awareness campaigns, Bendler isn’t asking for donations or signing people up for programmes. His message is individual and internal:

  • Walk without headphones. “You don’t have to surveil anyone—just notice things. How people move. What they avoid. What they say on the phone. What they don’t.”

  • Write things down. “Not for memory—for clarity. If you can’t write it clearly, you probably don’t understand it clearly.”

  • Resist the need to respond instantly. “Observation teaches restraint. Sometimes, the best move is no move at all.”

  • Follow long-form news and intelligence analysis. “There’s a growing wave of sharp independent voices offering deeper context. Find them.”

A Veteran’s Reflections on Modern Threats

Though retired from official service, Bendler remains engaged with geopolitical developments and risk analysis. He supports the emergence of decentralised intelligence communities—independent analysts and writers using open-source tools to assess global trends.

“A PhD candidate in Buenos Aires tracking military radio frequencies can sometimes outthink an entire agency. That excites me.”

But Bendler is equally wary of what he calls “performative analysis”—quick takes masquerading as insight.

“The smartest thing you can say sometimes is: I don’t know yet. Let me look longer.”

A Lesson from Failure

Bendler also shared one of his most defining lessons from the field—a near-fatal delay in pulling an asset from a compromised area.

“They survived, but barely. It taught me never to let operational optimism override gut discomfort. Listen to the unease. It’s there for a reason.”

That experience now shapes how he approaches everything from decision-making to public commentary.

A Final Word

“The world’s getting louder,” Bendler concluded. “But that doesn’t mean we have to. If more people chose quiet observation over immediate reaction, we’d all be a little wiser—and a lot harder to manipulate.”

What You Can Do Today

  • Take a 15-minute walk in your neighbourhood with no phone, music, or podcasts. Just observe.

  • Spend one day writing down every decision you make. Then review it—what was reactive, and what was intentional?

  • Read one long-form article on geopolitics or behavioural psychology from a source outside your usual media bubble.

  • Talk to someone in person about something meaningful—and listen fully.

Media Contact: Read the full interview, here.

Email: dalebendler@emaildn.com

About Dale Bendler:

Dale Bendler is a retired CIA Chief of Station and former Force Recon Marine with a career spanning over 30 years. He has led covert operations, trained agents worldwide, and continues to study global affairs with discipline and discernment. He lives a quiet life centred on physical training, language learning, and reflective analysis, alongside his wife of 30 years, Sandra.

Media Contact
Contact Person: Dale Bendler
Email: Send Email
Country: United States
Website: https://www.dalebendler.com/

ProCare Carpet & Tile Cleaning Announces Back-to-School Cleaning Specials for Modesto Families

ProCare Carpet & Tile Cleaning Announces Back-to-School Cleaning Specials for Modesto Families
Local cleaning experts offer discounted services to help families prepare for the new school year

MODESTO, CA – August 7, 2025 – As families across Modesto prepare for the back-to-school season, ProCare Carpet & Tile Cleaning is making it easier than ever to start the school year with a fresh, clean home. The locally-owned cleaning company is announcing special promotional pricing on their comprehensive cleaning services throughout the back-to-school period.

“We understand that the start of a new school year is both exciting and stressful for families,” said Louis Reid, owner of ProCare Carpet & Tile Cleaning. “Between shopping for supplies, new clothes, and getting back into routines, home cleaning often takes a backseat. Our back-to-school specials are designed to help busy parents check deep cleaning off their to-do list without breaking the budget.”

ProCare Carpet & Tile Cleaning

Since 2005, ProCare Carpet & Tile Cleaning has been Modesto’s trusted partner for residential and commercial cleaning services. With nearly two decades of experience serving the Central Valley, the family-owned business has built a reputation for reliable, thorough, and affordable cleaning solutions.

ProCare Carpet & Tile Cleaning’s comprehensive services include professional carpet cleaning using state-of-the-art equipment and eco-friendly solutions that remove deep-seated dirt, allergens, and stains. Their upholstery cleaning services restore furniture to like-new condition, while their specialized tile and grout cleaning revitalizes bathroom and kitchen surfaces that see heavy daily use.

ProCare also offers expert stone cleaning and restoration services for natural stone surfaces, ensuring that marble, granite, and other stone features maintain their beauty and durability. Each service is performed by trained technicians who understand the unique cleaning requirements of different materials and surfaces.

“A clean home environment contributes to better health and peace of mind,” Reid explained. “When families return to their school routines, they deserve to come home to spaces that are not only clean but also healthier. Our deep cleaning services remove allergens, bacteria, and pollutants that regular household cleaning might miss.”

The back-to-school cleaning specials are available for a limited time and can be customized to meet each family’s specific needs and budget. Whether customers need a single room refreshed or a whole-house deep clean, ProCare’s flexible scheduling accommodates busy family calendars.

ProCare Carpet & Tile Cleaning serves residential and commercial clients throughout Modesto and the surrounding Central Valley communities. The company is fully licensed, insured, and committed to customer satisfaction.

Families interested in taking advantage of the back-to-school cleaning specials are encouraged to call (209) 523-2273 or fill out the quote form on the company’s website for a free, no-obligation estimate. ProCare’s team can provide detailed information about services and help customers choose the cleaning package that best meets their needs.

About ProCare Carpet & Tile Cleaning

Founded in 2005, ProCare Carpet & Tile Cleaning is a locally-owned cleaning company serving Modesto, California, and surrounding communities. The company specializes in carpet cleaning, upholstery cleaning, tile and grout cleaning, and stone restoration services for residential and commercial clients.

Contact:

Louis Reid

ProCare Carpet & Tile Cleaning

224 Eagle Ct, Modesto, CA 95350

Phone: (209) 523-2273

Email: procareldr@gmail.com

Website: https://procaremodesto.com/

Media Contact
Company Name: ProCare Carpet & Tile Cleaning
Contact Person: Louis Reid
Email: Send Email
Address:224 Eagle Ct
City: Modesto
State: CA
Country: United States
Website: https://procaremodesto.com/